This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Julina for postmenopausal osteoporosis. The objective of this study is to assess safety and efficacy of using Julina in clinical practice. A total 100 patients will be recruited and followed 3 years since starting Julina administration.
Study Type
OBSERVATIONAL
Enrollment
506
Patients in daily life treatment receiving Julina for postmenopausal osteoporosis
Unnamed facility
Multiple Locations, Japan
Incidence of adverse drug reactions and serious adverse events in subject who received Julina
Time frame: After Julina administration, upto 1 year
Incidence of adverse drug reactions in subpopulation with baseline data (such as demographic data, concomitant disease) and dose of Julina
Time frame: At baseline and after Julina administration, upto 1 year
Change from baseline in grad of hot flush and sweating at the end of Julina treatment
Time frame: At baseline and at end of Julina treatment, upto 1 year
Change from baseline in with/without vaginal atrophy at the end of Julina treatment
Time frame: At baseline and at end of Julina treatment, upto 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.